We found that the expression of PRSS3 and PRSS3-V2 was similarly downregulated but with a gradually increasing tendency in HCC tumors compared with control tissues, following the progression of tumor stages (Figure 6A) and pathological grades (Figure 6B), in which PRSS3-V2Low was significantly detected in tumors of early HCC patients in contrast to PRSS3-V2High in advanced tumors. The gene discussed is PRSS3; the disease is hepatocellular carcinoma.